Evidence map›Paper›PMID 40737580›Full record

ReviewJCO global oncology2025

First Decade of the National Cancer Institute's Affordable Cancer Technologies Program: Accelerating Translational Technology Research and Development for Cancer Globally.

Paul C Pearlman, Rao Divi, Rebecca Huppi, Elise Garton, Srivatsan Kidambi, Pushpa Tandon, Miguel Ossandon, Ophira Ginsburg, Satish Gopal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JCO global oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paul C PearlmanDepartment of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-7225-5019
Rao DiviDepartment of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Rebecca HuppiDepartment of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Elise GartonDepartment of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-3155-1812
Srivatsan KidambiDepartment of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Pushpa TandonDepartment of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-9615-7357
Miguel OssandonDepartment of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Ophira GinsburgDepartment of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-1384-2675
Satish GopalDepartment of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since 2014, the National Cancer Institute Affordable Cancer Technologies (ACTs) program has supported a broad research portfolio focused on the development and validation of new technologies for global cancer control. ACTs projects are conducted by international teams composed of investigators from the United States and low- and middle-income countries, spurring important contextually relevant innovations. During its first decade, the ACTs program ushered in new technology platforms, led to commercialized products, and affected health policies and programs worldwide including in the United States. It has allowed a new generation of investigators working across disciplines and national borders to pursue novel technological solutions and leverage new analytic methods to advance human health. This commentary lays out the scope and accomplishments of the ACTs program to date while considering possible future research directions.

Indexed as

NeoplasmsTranslational Research, BiomedicalHumansNational Cancer Institute (U.S.)United States

Identifiers

PMID40737580
PMCPMC12320939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.